Results 211 to 220 of about 8,187 (238)
Some of the next articles are maybe not open access.

In Vitro Activity of Cefiderocol on Multiresistant Bacterial Strains and Genomic Analysis of Two Cefiderocol Resistant Strains

Antibiotics, 2023
Giorgio Piccinelli   +2 more
exaly  

Catecholate Siderophore Receptor CirA Impacts Cefiderocol Susceptibility in Klebsiella pneumoniae

International Journal of Antimicrobial Agents, 2022
Xueqing Wu, Lan Peng, Jian-Cang Zhou
exaly  

Cefiderocol/cotrimoxazole

Reactions Weekly, 2023
openaire   +1 more source

Cefiderocol: A Comprehensive Review of Chemistry, Mechanisms of Resistance, and Clinical Applications in the Era of Multidrug Resistance

Current Microbiology
Mohammad Javad Roustaye Gourabi   +6 more
semanticscholar   +1 more source

Cefiderocol (S-649266)

2017
Cefiderocol (S-649266) is a novel siderophore cephalosporin, initially developed jointly by Shionogi Inc. and Glaxo Smith Kline. From November 9, 2015, further development was by Shio nogi alone. By virtue of in vitro activity against carbapenem- resistant Enterobacteriaceae (CRE), including those producing Klebsiella pneumoniae carbapenemase (KPC ...
openaire   +2 more sources

Home - About - Disclaimer - Privacy